LONDON--(BUSINESS WIRE)--Aug. 1, 2014-- The
The four year project will allow scientists to do pioneering new research to decode 100,000 human genomes - a patient's personal DNA code. The landmark project is on a scale not seen anywhere else in the world and is part of the Prime Minister's commitment to ensure the NHS as well as the
Sequencing the genome of a person with cancer or someone with a rare disease will help scientists and doctors understand how disease works. The project has the potential to transform the future of health care, with new and better tests, drugs and treatment. It is expected to provide a lifeline to thousands of families affected by rare genetic diseases and cancers.
The Prime Minister has pledged that the
Now, as world leading research organisations join forces, the 100,000
The Prime Minister is today unveiling a new partnership between Genomics
This research puts the NHS at the forefront of scientific discovery. This is in line with the Prime Minister's vision for the NHS to be the first mainstream health service in the world to offer genomic medicine as part of routine care.
"This agreement will see the
"As our plan becomes a reality, I believe we will be able to transform how devastating diseases are diagnosed and treated in the NHS and across the world, while supporting our best scientists and life science businesses to discover the next wonder drug or breakthrough technology."
The agreement will place Genomics England at the heart of one of the world's most vibrant genomic science and technology clusters, and allow scientists to work with world-class researchers from the
The cash injection - and new partnerships - will mean excellent progress can be made on the 100,000
Participation in the project will be based on consent, and people's data will be strictly protected through Genomics England's secure data services.
Life Sciences Minister
"Genomics England's ground breaking partnership with
"This project is also very important for the economy and the development of life sciences in this country - including creating valuable jobs in
"This is a real milestone in turning this ambitious project into what we always intended which is a world leading project capable of delivering immense benefit to current and future patients."
"This is a momentous day for the
“Illumina is committed to partnering with Genomics England as they look to implement vital changes in the way healthcare is practiced. This project confirms the
"Understanding humanity's genetic code is not only going to be fundamental to the medicine of the future. It is an essential part of medicine today. In rare congenital diseases, in cancer and in infections, genomic insights are already transforming diagnosis and treatment.
"The NHS is now set to become one of the world's 'go-to' health services for the development of innovative genomic tests and patient treatments, building on our long track record as the nation that brought humanity antibiotics, vaccines, modern nursing, hip replacements, IVF, CT scanners, and breakthrough discoveries from the circulation of blood to the existence of DNA.
"The NHS' comparative advantage in unlocking patient benefits from the new genomic revolution stems from our unique combination of a large and diverse population, with universal access to care, multi-year data that spans care settings, world-class medicine and science, and an NHS funding system that enables upstream investment in prevention and new ways of working, as demonstrated by this ground-breaking 100,000
Rare diseases are uncommon but there are between 5000 - 8000 known genetic disorders. Around three million people are affected by them, half of these are children. When the
Our understanding of how to use this information has also increased. We still have a lot to learn, but these advances have opened up the potential use of genomics medicine within mainstream healthcare.
- to bring benefit to patients
- to create an ethical and transparent programme based on consent
- to enable new scientific discovery and medical insights
- to kickstart the development of a
UKgenomics industry. The project is focusing on patients with rare diseases, and their families, as well as patients with common cancers. The project is currently in its pilot phase and the main project begins in 2015.
Illumina Forward-Looking Statements
This release may contain forward looking statements that involve risks and uncertainties. Important factors that could cause actual results to differ materially from those in any forward-looking statements are detailed in our filings with the
Senior Press Officer | Public Health
Jane Ellison Department of Health
T: 020 7210 5281